Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€180.68

€180.68

1.260%
2.24
1.260%
€200.00

€200.00

 
11.06.21 / Tradegate WKN: A2N9D9 / Symbol: MRNA / Name: Moderna / Stock / Mid Cap /
Latest predictions
-
26.04.21
22.08%
buy
-
20.02.21
25.39%
-
01.02.21
22.66%
-
27.01.21
34.70%
buy
-
04.12.20
44.82%
buy
€125.00
29.11.20
67.30%
buy
Best running prediction
€125.00
07.03.20
549.93%
buy
Your prediction

Moderna Inc. Stock

There is an upward development for Moderna Inc. compared to yesterday, with an increase of €2.24 (1.260%).
Currently there is a rather positive sentiment for Moderna Inc. with 14 Buy predictions and 3 Sell predictions.
As a result the target price of €200.00 shows a slightly positive potential of 10.693% compared to the current price of €180.68 for Moderna Inc..
For the coming years our community has positive and negative things to say abot the Moderna Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Non-cyclic/Cyclic" there were negative voices in the community.

Pros and Cons of Moderna Inc. in the next few years

Pros
8
Could be worthwhile Investment >10% per year
3
Revenue growth > 30% per year expected
3
Very Future proof/growth oriented business model
Cons
4
Significant cyclical dependencies
2
Few uniques

Comments

Buy Moderna Inc.
Show more

Sell Moderna Inc.
Show more

Buy Moderna Inc.
Show more

Other discussions about Moderna Inc. Stock

Trading Moderna Inc.

Trading Moderna Inc.

New thread Forum

News

Swissmedic Authorizes COVID-19 Vaccine Moderna for Use in Switzerland: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg
Swissmedic Authorizes COVID-19 Vaccine Moderna for Use in Switzerland


Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has

Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines : https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines


Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its pipeline of innovative vaccines with three

United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna: https://mms.businesswire.com/media/20210106005629/en/850492/5/KO_LOGO_%28002%29.jpg
United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna


Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the UK’s Medicines and Healthcare products Regulatory Agency